NDC 65293-005-50: 50 mL vial
NDC 65293-005-00: 100 mL vial

Storage
Leave vials in cartons until use. Clevidipine is photosensitive and storage in cartons protects against photodegradation. Protection from light during administration is not required.

Store vials refrigerated at 2-8°C (36-46°F). Do not freeze. Vials in cartons may be transferred to 25°C (77°F, USP controlled room temperature) for a period not to exceed 2 months. Upon transfer to room temperature, mark vials in cartons “This product was removed from the refrigerator on _/_/_ date. It must be used or discarded 2 months after this date or the labeled expiration date (whichever date comes first).” Do not return to refrigerated storage after beginning room temperature storage.

Handling

Maintain aseptic technique while handling Cleviprex. Cleviprex is a single-use parenteral product that contains 0.005% disodium edetate to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental contamination. However, Cleviprex can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Once the stopper is punctured, use within 12 hours and discard any unused portion.

Cleviprex inhibits microbial growth for up to 12 hours, as demonstrated by test data for representative USP microorganisms, staphylococcus epidermidis and serratia marcescens.

17PATIENT COUNSELING INFORMATION
Advise patients with underlying hypertension that they require continued follow up for their medical condition, and, if applicable, encourage patients to continue taking their oral antihypertensive medication(s) as directed.
Advise patients to contact a healthcare professional immediately for any of the following signs of a new hypertensive emergency: neurological symptoms, visual changes, or evidence of congestive heart failure.
Manufactured by:
Fresenius Kabi Austria GmbH, Graz, Austria
Marketed by:
The Medicines Company
Parsippany, New Jersey 07054

For information call: 888-977-MDCO (6326)

US Patent 5,856,346
US Patent 5,739,152

TMC PN 1220 (April 28, 2011)

Package Label - Principal Display Panel - 25mg/50mL Container

Package Label - Principal Display Panel - 25mg/50mL Inner Carton

Package Label - Principal Display Panel - 50mg/100mL Container

Package Label - Principal Display Panel - 50mg-100mL Outer Carton

CLEVIPREX
clevidipine emulsion
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65293-005
Route of Administration INTRAVENOUS DEA Schedule 
 
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLEVIDIPINE (CLEVIDIPINE)  CLEVIDIPINE 0.5mg in1mL
 
Inactive Ingredients
Ingredient Name Strength
SOYBEAN OIL 
GLYCERIN 
EGG PHOSPHOLIPIDS 
EDETATE DISODIUM 
OLEIC ACID 
SODIUM HYDROXIDE 
WATER 
NITROGEN 
 
Product Characteristics
Color WHITE (Milky)  Score 
Shape  Size 
Flavor  Imprint Code 
Contains